Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
The study objective is to compare the efficacy and the safety of masitinib at 6 mg/kg/day
versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral
corticosteroids.